{"product_id":"iminosugars-9780470033913","title":"Iminosugars","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eGathering the major world experts in the field, Iminosugars: From Synthesis to Therapeutic Applications provides an up-to-date account of many contemporary aspects of iminosugars from organic synthesis to clinical studies. The first chapter gives a historical narrative of iminosugars and a general presentation of the organization of the book.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\"This is book is a must buy for anyone interested in carbohydrate and\/or medicinal chemistry.\" (\u003ci\u003eJournal of the American Chemical Society\u003c\/i\u003e, May 14, 2008)  \u003cp\u003e\"Given the recent resurgence of interest in this class of compounds, the text is a welcome review of the area.\" (\u003ci\u003eJournal of Medicinal Chemistry\u003c\/i\u003e, 2008)\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eForeward.  \u003cp\u003ePreface.\u003c\/p\u003e \u003cp\u003eList of Contributors.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1. Iminosugars: past, present and future\u003c\/b\u003e (Philippe Compain and Olivier R. Martin).\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Naturally occurring iminosugars and related alkaloids: structure, activity and applications\u003c\/b\u003e (Naoki Asano).\u003c\/p\u003e \u003cp\u003e2. Introduction.\u003c\/p\u003e \u003cp\u003e2.2 α-Glucosidase inhibitors.\u003c\/p\u003e \u003cp\u003e2.3 ß-Glucosidase inhibitors.\u003c\/p\u003e \u003cp\u003e2.4 α- and b-Galactosidase inhibitors.\u003c\/p\u003e \u003cp\u003e2.5 α-Mannosidase inhibitors.\u003c\/p\u003e \u003cp\u003e2.6 Concluding remarks and future prospects.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3. General strategies for the synthesis of iminosugars and new approaches towards iminosugar libraries.\u003c\/b\u003e (Barbara la Ferla, Laura Cipolla and Francesco Nicotra)\u003c\/p\u003e \u003cp\u003e3.1 Introduction.\u003c\/p\u003e \u003cp\u003e3.2 Monocyclic compounds.\u003c\/p\u003e \u003cp\u003e3.3 1-N-Iminosugars.\u003c\/p\u003e \u003cp\u003e3.4 Bicyclic compounds.\u003c\/p\u003e \u003cp\u003e3.5 Other bicyclic compounds.\u003c\/p\u003e \u003cp\u003e3.6 Iminosugar conjugates.\u003c\/p\u003e \u003cp\u003e3.7 Conclusions.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4. Iminosugar C-glycosides: synthesis and biological activity\u003c\/b\u003e (Philippe Compain).\u003c\/p\u003e \u003cp\u003e4.1 Introduction.\u003c\/p\u003e \u003cp\u003e4.2 Synthesis of iminosugar C-glycosides.\u003c\/p\u003e \u003cp\u003e4.3 Biological activity of iminosugar C-glycosides.\u003c\/p\u003e \u003cp\u003e4.4 Conclusion.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5. Imino-C-disaccharides and analogues: synthesis and biological activity\u003c\/b\u003e (Pierre Vogel, Sandrine Gerber-Lemaire and Lucienne Juillerat-Jeanneret).\u003c\/p\u003e \u003cp\u003e5.1 Introduction.\u003c\/p\u003e \u003cp\u003e5.2 Synthesis of imino-C-disaccharides.\u003c\/p\u003e \u003cp\u003e5.3 Conformations of imino-C-disaccharides.\u003c\/p\u003e \u003cp\u003e5.4 Glycosidase inhibitory activities of imino-C-disaccharides.\u003c\/p\u003e \u003cp\u003e5.5 Efficient combinatorial method for the discovery of glycosidase inhibitors.\u003c\/p\u003e \u003cp\u003e5.6 Antitumour activity of new a-mannosidase inhibitors.\u003c\/p\u003e \u003cp\u003e5.7 Conclusion.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6. Isofagomine, noeuromycin and other 1-azasugars, iminosugar related glycosidase inhibitors\u003c\/b\u003e (Oscar Lopez and Mikael Bols).\u003c\/p\u003e \u003cp\u003e6.1 Introduction.\u003c\/p\u003e \u003cp\u003e6.2 1-Azasugars that are piperidines (isofagomine, noeuromycin, etc.).\u003c\/p\u003e \u003cp\u003e6.3 1-Azasugars that are hydrazines\u003c\/p\u003e \u003cp\u003e6.4 1-Azasugars that are oxazines.\u003c\/p\u003e \u003cp\u003e6.5 1-Azasugars that are piperidones.\u003c\/p\u003e \u003cp\u003e6.6 Sulphur-containing analogues of 1-azasugars.\u003c\/p\u003e \u003cp\u003e6.7 Slow inhibition and thermodynamics of binding.\u003c\/p\u003e \u003cp\u003e6.8 Are 1-azasugars (and iminosugars) transition state analogues?\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7. Iminosugar-based glycosyltransferase inhibitors\u003c\/b\u003e (Lisa J. Whalen, William A. Greenberg, Michael L. Mitchell and Chi-Huey Wong).\u003c\/p\u003e \u003cp\u003e7.1 Biological role and structural features of glycosyltransferases.\u003c\/p\u003e \u003cp\u003e7.2 Development of inhibitors of glycosyltransferases.\u003c\/p\u003e \u003cp\u003e7.3 Conclusion.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8. Transition state analogue inhibitors of N-Ribosyltransferases\u003c\/b\u003e (Vern L. Schramm and Peter C. Tyler).\u003c\/p\u003e \u003cp\u003e8.1 Introduction.\u003c\/p\u003e \u003cp\u003e8.2 Nucleoside hydrolases.\u003c\/p\u003e \u003cp\u003e8.3 Purine nucleoside phosphorylases (PNPs).\u003c\/p\u003e \u003cp\u003e8.4 5’-Methylthioadenosine (MTA) nucleosidases and phosphorylases.\u003c\/p\u003e \u003cp\u003e8.5 Ricin A-chain.\u003c\/p\u003e \u003cp\u003e8.6 Summary and conclusions.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9. Iminosugars as antiviral agents\u003c\/b\u003e (Pamela A. Norton, Baohua Gu, and Timothy M. Block).\u003c\/p\u003e \u003cp\u003e9.1 Introduction.\u003c\/p\u003e \u003cp\u003e9.2 The relationship between glucosidase inhibition and antiviral action.\u003c\/p\u003e \u003cp\u003e9.3 Fate of viral glycoproteins in glucosidase-inhibited cells.\u003c\/p\u003e \u003cp\u003e9.4 Specificity of glucosidase inhibition.\u003c\/p\u003e \u003cp\u003e9.5 N-Alkyl DNJs inhibit virus growth by non-glucosidase inhibitory mechanisms – other potential activities of these compounds.\u003c\/p\u003e \u003cp\u003e9.6 New directions for improving glucosidase inhibitors as antiviral agents.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10. Iminosugars as active-site-specific chaperones for the treatment of lysosomal storage disorders.\u003c\/b\u003e (Jian-Qiang Fan)\u003c\/p\u003e \u003cp\u003e10.1 Introduction.\u003c\/p\u003e \u003cp\u003e10.2 Degradation of glycosphingolipids.\u003c\/p\u003e \u003cp\u003e10.3 Lysosomal enzyme biosynthesis and ER-associated degradation (ERAD).\u003c\/p\u003e \u003cp\u003e10.4 Active-site-specific chaperones and iminosugars.\u003c\/p\u003e \u003cp\u003e10.5 Basic requirements for effective ASSCs.\u003c\/p\u003e \u003cp\u003e10.6 Identification of ASSCs.\u003c\/p\u003e \u003cp\u003e10.7 Examples of ASSC therapy for lysosomal storage disorders.\u003c\/p\u003e \u003cp\u003e10.8 Future perspectives.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11. Iminosugar inhibitors for substrate reduction therapy for the lysosomal glycosphingolipidoses\u003c\/b\u003e (Terry D. Butters).\u003c\/p\u003e \u003cp\u003e11.1 Glycolipid lysosomal storage diseases.\u003c\/p\u003e \u003cp\u003e11.2 Options for glycosphingolipidosis therapy.\u003c\/p\u003e \u003cp\u003e11.3 Iminosugars for substrate reduction therapy.\u003c\/p\u003e \u003cp\u003e11.4 Iminosugars as inhibitors of glycolipid biosynthesis.\u003c\/p\u003e \u003cp\u003e11.5 SRT combination therapy.\u003c\/p\u003e \u003cp\u003e11.6 Prospects for iminosugars as therapeutics.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12. Iminosugar-based antitumoural agents\u003c\/b\u003e (Yoshio Nishimura).\u003c\/p\u003e \u003cp\u003e12.1 Introduction.\u003c\/p\u003e \u003cp\u003e12.2 Hexose-mimetic iminosugars.\u003c\/p\u003e \u003cp\u003e12.3 Hexuronic acid-mimetic iminosugars.\u003c\/p\u003e \u003cp\u003e12.4 Concluding remarks.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Medicinal use of iminosugars\u003c\/b\u003e (Timothy M. Cox, Frances M. Platt and Johannes M. F. G. Aerts).\u003c\/p\u003e \u003cp\u003e13.1 Introduction.\u003c\/p\u003e \u003cp\u003e13.2 Recent pharmaceutical developments.\u003c\/p\u003e \u003cp\u003e13.3 Clinical application of iminosugars as medicines.\u003c\/p\u003e \u003cp\u003e13.4 Conclusions.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Tables of iminosugars, their biological activities and their potential as therapeutic agents\u003c\/b\u003e (Philippe Compain, Valérie Desvergnes, Virginie Liautard, Christelle Pillard and Sylvestre Toumieux).\u003c\/p\u003e \u003cp\u003e14.1 Introduction.\u003c\/p\u003e \u003cp\u003e14.2 Type 2 diabetes.\u003c\/p\u003e \u003cp\u003e14.3 Antiviral activities.\u003c\/p\u003e \u003cp\u003e14.4 Antibacterial activities.\u003c\/p\u003e \u003cp\u003e14.5 Antiprotozoal activities.\u003c\/p\u003e \u003cp\u003e14.6 Antiparasitarial activities.\u003c\/p\u003e \u003cp\u003e14.7 Cancer.\u003c\/p\u003e \u003cp\u003e14.8 Lysosomal diseases.\u003c\/p\u003e \u003cp\u003e14.9 Immunomodulating agents.\u003c\/p\u003e \u003cp\u003e14.10 Antipsoriatic agents.\u003c\/p\u003e \u003cp\u003e14.11 Antifungal agents.\u003c\/p\u003e \u003cp\u003e14.12 Cystic fibrosis.\u003c\/p\u003e \u003cp\u003e14.13 Infertility inducing agents.\u003c\/p\u003e \u003cp\u003e14.14 Chondroprotective agents.\u003c\/p\u003e \u003cp\u003e14.15 Inflammatory diseases.\u003c\/p\u003e \u003cp\u003e14.16 Appetite suppressing agents.\u003c\/p\u003e \u003cp\u003e14.17 Nematicidal activity.\u003c\/p\u003e \u003cp\u003e14.18 Insecticidal activity.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003eIndex.\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":51767547560279,"sku":"9780470033913","price":138.56,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780470033913.jpg?v=1758713730","url":"https:\/\/bookcurl.com\/products\/iminosugars-9780470033913","provider":"Book Curl","version":"1.0","type":"link"}